12 0

(Reuters) - The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc’s ( GILD.O ) remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation. FILE PHOTO: An ampule of remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS/File Photo. The peer-reviewed data was published in the New England Journal of Medicine. The trial, for which final results are still trickling in, showed that recovery time for pati... Full story

23 May